May 16 (Reuters) - Pfizer Inc will buy Anacor Pharmaceuticals Inc in a deal valued at $5.2 billion, net of cash, for access to Anacor's non-steroidal topical gel to treat eczema.
Pfizer will pay $99.25 per share for Anacor, a 55 percent premium to the stock's Friday close, the companies said on Monday.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ((penumudi.amrutha@thomsonreuters.com; within U.S. +1 646 223 8780 outside U.S. +91 80 6749 4486; Reuters Messaging: penumudi.amrutha.thomsonreuters.com@reuters.net))
Pfizer will pay $99.25 per share for Anacor, a 55 percent premium to the stock's Friday close, the companies said on Monday.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ((penumudi.amrutha@thomsonreuters.com; within U.S. +1 646 223 8780 outside U.S. +91 80 6749 4486; Reuters Messaging: penumudi.amrutha.thomsonreuters.com@reuters.net))
